SomaLogic, Inc. (SLGC)
Company Description
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States.
It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples.
The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development.
Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others.
The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions.
The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits.
The company was founded in 1999 and is headquartered in Boulder, Colorado.
| Country | United States |
| Founded | 2000 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 451 |
| CEO | Adam Taich |
Contact Details
Address: C/o Somalogic, Inc., 2945 Wilderness Place Boulder, Colorado 80301 United States | |
| Phone | (303) 625-9000 |
| Website | somalogic.com |
Stock Details
| Ticker Symbol | SLGC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001837412 |
| CUSIP Number | 83444K105 |
| ISIN Number | US83444K1051 |
| Employer ID | 85-4298912 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Troy M. Cox M.B.A. | Executive Chairman |
| Dr. Roy Smythe M.D. | Chief Executive Officer and Director |
| Shaun M. Blakeman | Chief Financial Officer |
| Dr. Jason Cleveland Ph.D. | Chief Technology Officer |
| Dr. Nebojsa Janjic Ph.D. | Chief Science Officer |
| Ruben Gutierrez J.D. | General Counsel |
| Alison Marie Roelke | Senior Vice President of People and Culture |
| Dr. Stephen A. Williams BS, MB, Ph.D. | Chief Medical Officer |
| Todd Johnson | Executive Vice President of Diagnostics Business Unit |
| Adam Taich | Executive Vice President of Life Sciences Business Unit |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 21, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 21, 2023 | 8-K | Current Report |
| Nov 8, 2023 | 10-Q | Quarterly Report |
| Nov 8, 2023 | 8-K | Current Report |
| Nov 8, 2023 | 425 | Filing |
| Oct 4, 2023 | 425 | Filing |
| Oct 4, 2023 | 425 | Filing |
| Oct 4, 2023 | 425 | Filing |
| Oct 4, 2023 | 425 | Filing |
| Oct 4, 2023 | 425 | Filing |